| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 30 Jan 2026 | 51 | 41% | 14% | 45% | 43% |
| 01 Jan 2025 - 30 Jun 2025 | 05 Aug 2025 | 50 | 41% | 16% | 43% | 8% |
| 30 Jun 2024 - 30 Dec 2024 | 24 Jan 2025 | 77 | 16% | 15% | 69% | 35% |
| 31 Dec 2023 - 29 Jun 2024 | 29 Jul 2024 | 75 | 14% | 18% | 68% | 35% |
| 30 Jun 2023 - 30 Dec 2023 | 31 Jan 2024 | 75 | 14% | 18% | 68% | 66% |
| 30 Jun 2022 - 30 Dec 2022 | 30 Jan 2023 | 69 | 19% | 21% | 60% | 40% |
| 31 Dec 2021 - 29 Jun 2022 | 29 Jul 2022 | 60 | 23% | 32% | 45% | 33% |
| 30 Jun 2021 - 30 Dec 2021 | 31 Jan 2022 | 64 | 19% | 45% | 36% | 26% |
| 31 Dec 2020 - 29 Jun 2021 | 22 Jul 2021 | 52 | 24% | 54% | 22% | 29% |
| 30 Jun 2020 - 30 Dec 2020 | 18 Jan 2021 | 66 | 15% | 43% | 42% | 30% |
| 31 Dec 2019 - 29 Jun 2020 | 14 Jul 2020 | 54 | 21% | 52% | 27% | 36% |
| 30 Jun 2019 - 30 Dec 2019 | 16 Jan 2020 | 50 | 24% | 55% | 21% | 29% |
| 31 Dec 2018 - 29 Jun 2019 | 25 Jul 2019 | 48 | 27% | 58% | 15% | 29% |
| 30 Jun 2018 - 30 Dec 2018 | 24 Jan 2019 | 45 | 38% | 50% | 12% | 29% |
| 31 Dec 2017 - 29 Jun 2018 | 18 Jul 2018 | 46 | 39% | 44% | 17% | 34% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Standard payment terms are 90 days from the date of receipt of a valid and correct invoice
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
In the first instance disputes will be received by our S2P contact centre at the defined email address or telephone number printed on every Purchase Order. Queries will then be forwarded to the requester of the services/goods for information and evaluation. Failure to meet resolution will be escalated to the S2P Business Partner and include the specific Buyer for the service/goods that is responsible for the vendor relationship.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
AVENTIS PHARMA LIMITED is a global pharmaceutical company that focuses on developing and manufacturing innovative medicines and healthcare solutions. The company was founded in 1999 and is headquartered in Paris, France. AVENTIS PHARMA LIMITED is a subsidiary of Sanofi, a multinational pharmaceutical company.
The company's sustainability program is integrated into its business strategy, with a focus on environmental, social, and economic responsibility. AVENTIS PHARMA LIMITED is committed to reducing its carbon footprint and implementing sustainable practices in its operations. It also has a strong focus on promoting diversity and inclusion within its workforce.
AVENTIS PHARMA LIMITED offers a wide range of products and services in various therapeutic areas, including cardiovascular, diabetes, oncology, and rare diseases. Its portfolio includes both prescription and over-the-counter medicines, as well as vaccines and consumer healthcare products.
The key people at AVENTIS PHARMA LIMITED include its CEO, Olivier Brandicourt, and its Chairman of the Board of Directors, Serge Weinberg. The company has a team of over 100,000 employees worldwide who work towards its mission of improving healthcare and making a positive impact on people's lives.
For more information on AVENTIS PHARMA LIMITED, including its products and services, investors, and sustainability efforts, please visit their website at www.aventispharma.com. The company's registered office address is 174 Avenue de France, 75013 Paris, France.
Proud of your payment record? Show your live score on your own site:
<iframe src="https://paymentcheck.co.uk/badge/01535640" width="240" height="72" style="border:0" title="PaymentCheck Score" loading="lazy"></iframe>